RSV vaccination in older adults significantly reduced cases of lower respiratory tract disease and deaths, with updated recommendations for high-risk groups. Nirsevimab effectively reduced ...
An interim analysis of safety data showed no increased risk associated with Pfizer’s respiratory syncytial virus vaccine when ...
CLEVELAND, Ohio — Nationally, respiratory syncytial virus and COVID-19 activity remains relatively low, due to population immunity, new vaccines for respiratory syncytial virus, and no new virulent ...
A common flu strain this season may be partially resistant to the vaccine. COVID-19 levels in Erie wastewater have remained low, with no recent hospital admissions. Erie County's 2025-26 respiratory ...
Respiratory virus season is upon the United States as the cold weather months set in, meaning cases of COVID-19, influenza and RSV are set to increase. In its annual outlook report, the Centers for ...
A significant percentage of U.S. adults have risk factors for severe RSV, yet vaccine uptake remains low, especially among eligible populations. Current RSV vaccine guidelines focus on older adults, ...
After winning an initial U.S. nod in July 2023, Beyfortus has gone on to do gangbusters for Sanofi and AZ, growing total sales 9.5% last year for a total haul of 1.78 billion euros (roughly $2.1 ...
The Vaccine Integrity Project, in collaboration with the American Medical Association (AMA), has announced the kickoff of a ...
Respiratory syncytial virus (RSV) vaccines were an estimated 79% effective against dangerous virus-related blood clots among ...
Market normalization reflects maturation, not decline - strategic transition creates opportunities in precision immunization, platform innovation, and targeted high-risk population protectionDelray ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results